All In Biotech

Drug Trial Radar · NCT02926898

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome (Cohort 2)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

87

Actual

Start

Jan 27, 2017

Primary completion

Jun 5, 2018

Study completion Jun 5, 2018

Sponsor

Sponsor type
Industry
First posted
Oct 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.

Conditions

  • Dravet Syndrome

Interventions

  • ZX008 (Fenfluramine Hydrochloride)Drug

    ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. \*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.

  • Matching PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) PeriodTime frame: 15 weeks (combined Titration + Maintenance Period)

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Children'S Hospital Colorado

    Aurora, Colorado

  • Ann & Robert H. Lurie Children'S Hospital of Chicago

    Chicago, Illinois

  • Children'S Hospital of Michigan

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Bc Children'S Hospital Division of Neurology

    Vancouver, British Columbia, Canada

  • Chu Sainte-Justine Hospital Neurology Clinic

    Montreal, Quebec, Canada

  • Chu Amiens Picardie Service de Neurologie Pédiatrique

    Amiens, France

  • Chu de Bordeaux Hôpital Des Enfants

    Bordeaux, France

  • HÔPITAL FEMME-MÈRE-ENFANT Hôpital Service de Neurologie Pédiatrique

    Bron, France

  • Chru de Lille Hôpital Roger Salengro

    Lille, France

  • Hôpital de La Timone, Service de Neuro-Métabolisme Pédiatrique

    Marseille, France

  • Hôpital Necker-Enfants Malades

    Paris, France

  • Hôpital Robert-Debré

    Paris, France

  • Chu de Toulouse - Hôpital Des Enfants

    Toulouse, France

  • Hôpital D'Enfants Chur de Nancy

    Vandœuvre-lès-Nancy, France

  • Krankenhaus Mara, Epilepsie-Zentrum Bethel

    Bielefeld, Germany

  • Universitätsklinikum Schleswig-Holstein, Klinik Für Neuropädiatrie

    Kiel, Germany

  • Kleinwachau Sächsisches Epilepsiezentrum Radeberg

    Radeberg, Germany

  • Epilepsiecentrum Kempenhaeghe

    Heeze, Netherlands

  • Stichting Epilepsie Instellingen Nederland

    Zwolle, Netherlands

  • Hospital Sant Joan de Déu Barcelona

    Barcelona, Spain

  • Hospital Ruber Internacional-Servicio de Neurología

    Madrid, Spain

  • Cliníca Universidad de Navarra Nidad de Neuropediatría

    Pamplona, Spain

  • Alder Hey Children'S Nhs Foundation Trust, Littlewood'S Neurosciences Unit

    Liverpool, United Kingdom

  • Evelina London Children'S Hospital, Paediatric Neurosciences

    London, United Kingdom

  • Great Ormond Street Hospital For Children Nhs Foundation Trust

    London, United Kingdom

  • Royal Hospital For Children, Queen Elizabeth University, Institute of Neurosciences Hospital

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.